Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

793 results

Filters applied: . Clear all
Page 1
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.
Siebenhaar F, Broesby-Olsen S, Castells M, George TI, Livideanu CB, Alvarez-Twose I, Panse J, Barete S, Reiter A, Dybedal I, Akin C, Van Daele P, Radia DH, Cerquozzi S, Ustun C, Sabato V, Gotlib J, Rafferty M, DeAngelo DJ, Schafhausen P, Ungerstedt J, Ogbogu PU, Florell S, Wada DA, Rets A, Lin HM, Bidollari I, Hong J, Shaheen D, Lampson B, Hartmann K. Siebenhaar F, et al. Among authors: lin hm. J Am Acad Dermatol. 2026 Feb 12:S0190-9622(26)00221-5. doi: 10.1016/j.jaad.2026.02.025. Online ahead of print. J Am Acad Dermatol. 2026. PMID: 41690487 Free article.
Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.
Pedrani M, Salfi G, Pecoraro G, Puglisi M, Turco F, Tortola L, Urechie V, Leone G, Lin HM, Vogl U, Barizzi J, Treglia G, Cuzzocrea M, Paone G, Lai P, Theurillat JP, Zilli T, Gillessen S, Merler S, Pereira Mestre R. Pedrani M, et al. Among authors: lin hm. Eur Urol Oncol. 2026 Feb 10:S2588-9311(26)00032-5. doi: 10.1016/j.euo.2026.01.011. Online ahead of print. Eur Urol Oncol. 2026. PMID: 41672832 Free article. Review.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.
Gotlib J, Reiter A, Radia DH, Álvarez-Twose I, Deininger MW, George TI, Panse JP, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu C, Mesa RA, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lübke J, Bidollari I, Lin HM, Rylova SN, Dimitrijević S, Muñoz-González JI, DeAngelo DJ. Gotlib J, et al. Among authors: lin hm. Blood Adv. 2026 Jan 28:bloodadvances.2025017519. doi: 10.1182/bloodadvances.2025017519. Online ahead of print. Blood Adv. 2026. PMID: 41604606
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.
Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F. Saporita I, et al. Among authors: lin hm. Prostate Cancer Prostatic Dis. 2026 Jan 26. doi: 10.1038/s41391-026-01077-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2026. PMID: 41582208 Review.
793 results